Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Iris Research and Development LLC

Neither a doctor nor a teaching hospital

Research payments

$6,777,191

374 payments

Through program year 2025, Iris Research and Development LLC is reported as receiving $6,777,191 in research payments, across 374 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,755,038 80
2024 Research $1,869,789 59
2023 Research $355,085 24
2022 Research $724,581 26
2021 Research $447,320 44
2020 Research $582,296 78
2019 Research $1,043,083 63

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,831,454 11 payments
  2. Janssen Research & Development, LLC $1,316,949 78 payments
  3. Novartis Pharmaceuticals Corporation $916,550 18 payments
  4. Gilead Sciences, Inc. $622,415 47 payments
  5. AbbVie, Inc. $565,488 97 payments
  6. Mallinckrodt Enterprises LLC $400,000 2 payments
  7. Regeneron Pharmaceuticals, Inc. $275,446 26 payments
  8. Sanofi US Services Inc. $228,364 13 payments
  9. Ucb SA $176,527 12 payments
  10. EMD Serono, Inc. $130,111 40 payments
Studies the money was for Research payments · program years 2019–2025
  1. P4 Uncontrolled Gout FORWARD II $972,896 3 payments
  2. A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $664,132 1 payment
  3. An Open-Label, Multi-Center Protocol for Patients Who Have Completed A Previous Novartis Sponsored Secukinumab Study and Are Judged By the Investigator to Benefit From Continued Secukinumab Treatment $612,640 4 payments
  4. Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $432,281 30 payments
  5. Clinical Impact of Acthar in the Psoriatic Arthritis Patient $400,000 2 payments
  6. A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc $354,099 10 payments
  7. Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Nsaid Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $275,446 26 payments
  8. A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease $196,916 15 payments
  9. A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis $177,864 8 payments
  10. A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $136,058 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record